Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Carcinoma × capmatinib × Clear all

Phase

Status

Withdrawn 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 8 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Rectal Neoplasms 1 Noonan Syndrome 6 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Lung Neoplasms 1 Laryngeal Diseases 1 Gliosarcoma 1 Glioblastoma 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Carboplatin 7 Pemetrexed 5 pembrolizumab 4 Gemcitabine 4 osimertinib 3 Sorafenib 3 Paclitaxel 3 Interleukin-2 3 Cyclophosphamide 3 Cisplatin 3 seocalcitol 2 selinexor 2 patritumab 2 liposomal doxorubicin 2 interferon gamma-1b 2 fludarabine 2 Sunitinib 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Irinotecan 2 Erlotinib Hydrochloride 2 DNA 2 Celecoxib 2 Capecitabine 2 Bleomycin 2 Bevacizumab 2 Albumin-Bound Paclitaxel 2 130-nm albumin-bound paclitaxel 2 volociximab 1 thioredoxin reductase inhibitor AM12 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04816214 2024-03-05

GEOMETRY-E

Novartis

Phase 3 Terminated

6 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡